Replimune Group Inc
NASDAQ:REPL
Operating Margin
Replimune Group Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Replimune Group Inc
NASDAQ:REPL
|
731.5m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
326.7B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
156.4B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135.7B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.1B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.3B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.3B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.5B USD |
-5%
|
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Replimune Group Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet